Report cover image

Gene Synthesis Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2025-2034

Publisher Global Market Insights
Published Nov 12, 2025
Length 153 Pages
SKU # GMI20613854

Description

The Global Gene Synthesis Market was valued at USD 951.9 million in 2024 and is estimated to grow at a CAGR of 16.9% to reach USD 4.62 billion by 2034.

The market’s rapid expansion is fueled by growing demand for synthetic biology, rising adoption of gene therapies, increasing applications in vaccine development, and the emergence of AI-driven DNA design tools. Gene synthesis plays a foundational role in biotechnology, enabling precise construction of DNA sequences for R&D, therapeutic development, disease diagnostics, and biomanufacturing. The surge in CRISPR-based engineering, next-generation sequencing, and high-throughput synthesis systems continues to accelerate adoption across pharmaceutical, academic, and industrial biotechnology sectors. Furthermore, expanding investments from public institutions and private companies are enhancing accessibility to advanced synthesis services across global markets. The industry’s technological evolution, particularly automation, enzymatic synthesis, and semiconductor-based DNA assembly, supports faster turnaround times and greater accuracy, allowing researchers to work with increasingly complex genetic constructs. As gene therapies, personalized medicines, and engineered biologics gain prominence, gene synthesis has become indispensable to modern life sciences innovation.

Based on the method, the solid-phase synthesis segment generated USD 558.2 million in 2024. This method remains preferred due to its precision, scalability, and compatibility with automated high-throughput platforms, which significantly improve purity and error control during DNA assembly. Solid-phase synthesis is widely adopted across therapeutic R&D, diagnostics, and synthetic biology, especially for producing long and complex DNA sequences with high fidelity. Its continued evolution through improved coupling reagents, microarray-based platforms, and advanced error-correction systems strengthens its position as the most widely used synthesis approach in commercial and academic applications.

In terms of application, the gene and cell therapy development segment generated USD 419.7 million in 2024. The growing momentum of regenerative medicine, CAR-T therapies, gene editing, and personalized genetic treatments drives demand for highly precise, customizable gene constructs. Synthetic genes enable optimized vectors, regulatory elements, and therapeutic DNA sequences essential for advancing clinical pipelines. Supported by favorable regulatory frameworks, expanding clinical trials, and substantial funding in genomic medicine, this segment is expected to remain the core growth engine of the market.

North AmericaGene Synthesis Market generated USD 383.8 million in 2024, driven by advanced healthcare infrastructure, heavy R&D investments, supportive regulatory pathways, and a strong presence of leading biotechnology companies. The region benefits from extensive adoption of synthetic biology tools, CRISPR technology, and genomic research programs supported by agencies such as NIH, Genome Canada, and private venture capital. Increasing partnerships between biopharma companies, academic institutions, and contract research organizations (CROs) further stimulate the demand for large-scale, high-precision gene synthesis.

Key players operating in the Global Gene Synthesis Market include Thermo Fisher Scientific, GenScript, Integrated DNA Technologies (IDT), Twist Bioscience, Eurofins Genomics, Azenta Inc., and others, each focusing on expanding synthesis capacity, integrating advanced automation, and developing AI-enabled design platforms to meet rising global demand. Companies in the gene synthesis market are strengthening their competitive position through a combination of capacity expansion, technological innovation, and regional diversification. Leading players are investing heavily in automation, AI-driven DNA design tools, and high-throughput synthesis platforms to improve accuracy, reduce turnaround times, and support increasingly complex genetic constructs. Several companies are building new manufacturing facilities across North America, Europe, and Asia-Pacific to scale production and improve delivery speed. Strategic collaborations with biopharmaceutical firms, academic institutions, and CROs enable faster development of gene therapies, vaccines, and diagnostic tools.

Table of Contents

153 Pages
Chapter 1 Methodology
1.1 Industry coverage
1.2 Market scope and definitions
1.3 Research design
1.4 Market size estimates and calculations
1.4.1 Approach 1: Company revenue share analysis
1.4.2 Approach 2: Data mining approach (investor presentations)
1.4.3 Approach 3: Through company base pair production volume
1.5 Key trends for market estimates
1.6 Forecast model
1.7 Primary research & validation
1.7.1 Primary sources
1.7.2 Data mining sources
1.7.2.1 Paid sources 22
1.7.2.2 Public sources
Chapter 2 Executive Summary
2.1 Industry 360 degree synopsis
2.1.1 Business trends
2.1.2 Regional trends
2.1.3 Method trends
2.1.4 Services trends
2.1.5 Application trends
2.1.6 Complexity trends
2.1.7 End use trends
2.2 CXO Perspectives: Strategic Imperatives
2.2.1 Key decision points for industry executives
2.2.2 Critical success factors for market players
2.3 Future outlook and strategic recommendations
Chapter 3 Industry Insights
3.1 Industry ecosystem
3.1.1 Supplier landscape
3.1.2 Value addition at each stage
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rapid advancements in DNA synthesis technology
3.2.1.2 Growing investments in gene synthesis projects and synthetic biology R&D 41
3.2.1.3 Increased prevalence of genetic disorders and chronic disease
3.2.1.4 Rising adoption of gene therapy
3.2.2 Industry pitfall
3.2.2.1 Lack of skilled professionals
3.2.2.2 Complex gene synthesis techniques and high process cost
3.2.3 Market opportunities
3.2.3.1 Expansion of CRISPR-based gene editing applications
3.2.3.2 RNA-based vaccines and therapeutics development
3.3 Growth potential analysis
3.3.1 By method
3.3.2 By services
3.3.3 By application
3.3.4 By complexity
3.3.5 By end use
3.4 Regulatory landscape
3.4.1 North America
3.4.1.1 U.S. 54
3.4.1.2 Canada 55
3.4.2 Europe
3.4.3 Asia Pacific
3.5 Technology and innovation landscape
3.5.1 Current technologies
3.5.2 Emerging technologies and their impacts
3.6 Future market trends
3.7 Pricing analysis
3.8 Investment and funding landscape
3.9 Porter's analysis
3.10 PESTEL analysis
Chapter 4 Competitive Landscape
4.1 Introduction
4.1.1 Eurofins Scientific SE
4.1.2 GenScript
4.1.3 Integrated DNA Technologies, Inc
4.2 Company matrix analysis
4.3 Company market share analysis, 2024
4.3.1 Company market share analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Key developments
4.6.1 Mergers and acquisitions
4.6.2 Partnerships and collaborations
4.6.3 New service launches
4.6.4 Expansion plans
Chapter 5 Gene Synthesis Market, By Method
5.1 Solid-phase synthesis
5.2 PCR-based enzyme synthesis
5.3 Chip-based synthesis
Chapter 6 Gene Synthesis Market, By Services
6.1 Antibody DNA synthesis
6.2 Viral DNA synthesis
6.3 Other services
Chapter 7 Gene Synthesis Market, By Application
7.1 Gene and cell therapy development
7.2 Disease diagnosis
7.3 Vaccine development
7.4 Other applications
Chapter 8 Gene Synthesis Market, By Complexity
8.1 Standard gene synthesis
8.2 Complex gene synthesis
Chapter 9 Gene Synthesis Market, By End Use
9.1 Biopharmaceutical companies
9.2 Academic and research institutes
9.3 Contract research organizations
Chapter 10 Gene Synthesis Market, By Region
10.1 North America
10.2 Europe
10.3 Asia Pacific
10.4 Latin America
10.5 Middle East and Africa
Chapter 11 Company Profiles
11.1 Azenta, Inc. (GENEWIZ)
11.1.1 Financial Data
11.1.2 Service Landscape
11.1.3 Strategy Outlook
11.1.4 SWOT Analysis
11.2 Bio Basic Inc.
11.2.1 Financial Data
11.2.2 Service Landscape
11.2.3 SWOT Analysis
11.3 BIOMATIK
11.3.1 Financial Data
11.3.2 Service Landscape
11.3.3 SWOT Analysis
11.4 BIONEER CORPORATION
11.4.1 Financial Data
11.4.2 Service Landscape
11.4.3 SWOT Analysis
11.5 Eurofins Scientific SE
11.5.1 Financial Data
11.5.2 Service Landscape
11.5.3 SWOT Analysis
11.6 Gene Universal Inc.
11.6.1 Financial Data
11.6.2 Service Landscape
11.6.3 SWOT Analysis
11.7 GenScript
11.7.1 Financial Data
11.7.2 Service Landscape
11.7.3 Strategy Outlook
11.7.4 SWOT Analysis
11.8 Integrated DNA Technologies, Inc.
11.8.1 Financial Data
11.8.2 Service Landscape
11.8.3 Strategy Outlook
11.8.4 SWOT Analysis
11.9 Macrogen, Inc.
11.9.1 Financial Data
11.9.2 Service Landscape
11.9.3 SWOT Analysis
11.10 OriGene Technologies, Inc.
11.10.1 Financial Data
11.10.2 Service Landscape
11.10.3 SWOT Analysis
11.11 ProMab Biotechnologies, Inc.
11.11.1 Financial Data
11.11.2 Service Landscape
11.11.3 SWOT Analysis
11.12 ProteoGenix
11.12.1 Financial Data
11.12.2 Service Landscape
11.12.3 SWOT Analysis
11.13 Synbio Technologies
11.13.1 Financial Data
11.13.2 Service Landscape
11.13.3 SWOT Analysis
11.14 Thermo Fisher Scientific, Inc.
11.14.1 Financial Data
11.14.2 Service Landscape
11.14.3 SWOT Analysis
11.15 Twist Bioscience Corporation
11.15.1 Financial Data
11.15.2 Service Landscape
11.15.3 Strategy Outlook
11.15.4 SWOT Analysis

Search Inside Report

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us